Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma

Annals of Surgical Oncology

Volumn 11, Issue 10, 2004, Pages 934-940

  Utsunomiya, Tohru ^a   Inoue, Hiroshi ^a   Tanaka, Fumiaki ^a   Yamaguchi, Hiroshi ^a   Ohta, Mitsuhiko ^a   Okamoto, Masahiro ^a   Mimori, Koshi ^a   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Cancer testis antigen; Cholangiocarcinoma; Immunotherapy; MAGE

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; SCP ANTIGEN; SSX ANTIGEN; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOPLASM; DNA METHYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BILE DUCT TUMOR; BIOSYNTHESIS; CELL CULTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER TUMOR; MIDDLE AGED; PATHOLOGY;

AGED; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 16544375969     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.01.029     Document Type: Article

References (34)

1. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-20.
2. Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcome. J Am Coll Surg 1998;187:365-72.
3. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
4. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
5. Van den Eynde B, Peeters O, De BO, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
6. Gure AO, Türeci O, Sahin U, et al. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 1997;72:965-71.
7. Sahin U, Türeci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
8. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914-8.
9. Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 1998;95:5211-6.
10. Türeci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996;56:4766-72.
11. Inoue H, Mori M, Li J, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995;63:523-6.
12. Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995;109:1522-5.
13. Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996;224:183-8.
14. Fujie T, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann Oncol 1997;8:369-72.
15. Tahara K, Sadanaga N, Nagashima H, Kitano S, Mori M. MAGE-specific cytotoxic T lymphocytes require non-specific CD54 adherence receptors on carcinoma cells. Int J Oncol 2000;17:805-10.
16. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agents 5-Aza-2′- deoxycytidine. Cancer Res 1994;54:1766-71.
17. Cho B, Lee H, Jeong SW, et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Comm 2003;307:52-63.
18. Santos NR, Torensma R, de Vries TJ, et al. Heterogeneous expression of the SSX cancer/testis antigen in human melanoma lesions and cell lines. Cancer Res 2000;60:1654-62.
19. Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigen expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002;86:979-82.
20. Utsunomiya T, Hara Y, Kataoka A, et al. Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res 2002;8:2591-4.
21. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 1994;56:826-9.
22. Lethe B, Lucas S, Michaux L, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998;76:903-8.
23. Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001;85:713-20.
24. Utsunomiya T, Inoue H, Taguchi K, Shimada M, Sugimachi k, Mori M. G protein γ7 expression as a new clinicopathological marker in patients with intrahepatic cholangiocarcinoma. Arch Surg 2002;137:181-5.
25. Kocher T, Schultz TE, Gudat F, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
26. Landry C, Brasseur F, Spagnoli GC, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000;86:835-41.
27. Carrel S, Schreyer M, Spagnoli GC, Cerottini JC, Rimodi D. Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Int J Cancer 1996;67:417-22.
28. Tanaka F, Fujie T, Tahara K, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocyte antigen-A24. Cancer Res 1997;57:4465-8.
29. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999;80:169-72.
30. Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-84.
31. Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identification of HLA-24-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res 2004;10:890-6.
32. Jungbluth AA, Stockert E, Chen YT, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumors. Br J Cancer 2000;83:493-7.
33. Sadanaga N, Nagashima H, Tahara K, Yoshikawa Y, Mori M. The heterogeneous expression of MAGE-3 protein: difference between primary lesions and metastatic lymph nodes in gastric carcinoma. Oncol Rep 1999;6:975-7.
34. Tsuneyama K, Sasaki M, Shimonishi T, Nakanuma Y. Expression of MAGE-A3 in intrahepatic cholangioma and its precursor lesions. Pathol Int 2004;54:181-6.